13C17-Mycophenolic Acid
(Synonyms: 霉酚酸-(全碳-13)) 目录号 : GC49759An internal standard for the quantification of mycophenolic acid
Cas No.:1202866-92-9
Sample solution is provided at 25 µL, 10mM.
13C17-Mycophenolic acid is intended for use as an internal standard for the quantification of mycophenolic acid by GC- or LC-MS. Mycophenolic acid is an immunosuppressive microbial metabolite that has been found in P. brevicompactum.1,2 It is also an active metabolite of mycophenolate mofetil that is formed via carboxylesterase 1 (CES1) and CES2.3 Mycophenolic acid is an inhibitor of IMP dehydrogenase (IMPDH) type I and type II (IC50s = 32 and 11 nM, respectively, in cell-free assays) and inhibits DNA synthesis in L strain mouse fibroblasts when used at concentrations ranging from 0.1 to 10 µg/ml.4,5 It is active against several strains of C. albicans, C. parakrusei, C. tropicalis, and C. neoformans (MICs = 3.9-31.25 µg/ml), as well as various strains of S. aureus (MICs = 31.25-125 µg/ml).2 Mycophenolic acid (150 mg/kg) reduces splenomegaly in a mouse model of Friend virus-induced leukemia.6 It decreases the number of hemolytic plaque forming cells isolated from the spleen of mice immunized with sheep red blood cells (RBCs) when administered at doses ranging from 60 to 240 mg/kg.1 Formulations containing mycophenolic acid have been used as immunosuppressive agents in the prevention of organ transplant rejection.
1.Mitsui, A., and Suzuki, S.Immunosuppressive effect of mycophenolic acidJ. Antibiot. (Tokyo)22(8)358-363(1969) 2.Noto, T., Sawada, M., Ando, K., et al.Some biological properties of mycophenolic acidJ. Antibiot. (Tokyo)22(4)165-169(1969) 3.Fujiyama, N., Miura, M., Kato, S., et al.Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetilDrug Metab. Dispos.38(12)2210-2217(2010) 4.Watkins, W.J., Chen, J.M., Cho, A., et al.Phosphonic acid-containing analogues of mycophenolic acid as inhibitors of IMPDHBioorg. Med. Chem. Lett.16(13)3479-3483(2006) 5.Franklin, T.J., and Cook, J.M.The inhibition of nucleic acid synthesis by mycophenolic acidBiochem J.113(3)515-524(1969) 6.Williams, R.H., Lively, D.H., DeLong, D.C., et al.Mycophenolic acid: Antiviral and antitumor propertiesJ. Antibiot. (Tokyo)21(7)463-464(1968)
Cas No. | 1202866-92-9 | SDF | Download SDF |
别名 | 霉酚酸-(全碳-13) | ||
Canonical SMILES | O=[13C]1O[13CH2][13C]2=[13C]1[13C](O)=[13C]([13CH2][13CH]=[13C]([13CH2][13CH2][13C](O)=O)[13CH3])[13C](O[13CH3])=[13C]2[13CH3] | ||
分子式 | [13C]17H20O6 | 分子量 | 337.2 |
溶解度 | Acetonitrile: soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.9656 mL | 14.828 mL | 29.656 mL |
5 mM | 0.5931 mL | 2.9656 mL | 5.9312 mL |
10 mM | 0.2966 mL | 1.4828 mL | 2.9656 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet